CSIMarket Company Name, Ticker, Industry, else..
 
Theratechnologies Inc   (NASDAQ: THTX)
 
Price: $3.3900 $3.39 %
Day's High: $3.39 Week Perf: 0.00
Day's Low: $ 3.39 30 Day Perf: 4.63 %
Volume (M): 0 52 Wk High: $ 3.40
Volume (M$): $ 0 52 Wk Avg: $3.31
Open: $3.39 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 88
 Revenues (TTM) (Millions $) 86
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Theratechnologies Inc. is a Canadian biopharmaceutical company focused on developing and commercializing innovative therapies for patients with unmet medical needs. The company primarily concentrates on creating drugs for treating HIV-associated lipodystrophy, which is a condition characterized by abnormal fat redistribution and metabolic complications. Theratechnologies Inc. specializes in developing peptide-based therapies and has successfully brought one product, EGRIFTA, to the market. EGRIFTA is a treatment for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company is known for its strong research and development capabilities and its commitment to improving the quality of life for patients. Theratechnologies Inc. operates globally and collaborates with various partners and healthcare professionals to ensure its products are effectively distributed to those who need them.


   Company Address: 2015 Peel Street Montreal 0 QC
   Company Phone Number: 315-6607   Stock Exchange / Ticker: NASDAQ THTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AZN   -2.75%    
BMY   -0.7%    
JNJ   -2.63%    
MRK   -1.92%    
NVS   -3.77%    
SNY   -2.91%    
• View Complete Report
   



Business Update

Strategic Acquisition Proposals Highlight Competitive Challenges Facing Theratechnologies Inc.

Published Fri, Apr 11 2025 7:02 PM UTC

In recent developments, Future Pak, LLC has taken significant steps towards acquiring Theratechnologies Inc. (NASDAQ: THTX) by submitting two formal acquisition proposals since January 2023. The latest proposal offers a cash consideration ranging from $3.51 to $4.50 per share, placing the total enterprise value of the acquisition at approximately $255 million. This venture r...
Product Service News

February 13, 2025Montreal Theratechnologies Inc. (TSX TH) (NASDAQ THTX), a leading specialty b...

Published Fri, Feb 14 2025 12:21 PM UTC

Theratechnologies Resumes Distribution of EGRIFTA SV After FDA Clearance February 13, 2025Montreal Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a leading specialty biopharmaceutical company, proudly announced today that it has resumed the distribution of its flagship product, EGRIFTA SV (tesamorelin for injection). This critical step follows the receipt of corresponden...
Management Announcement

Theratechnologies Faces Supply Crisis Amidst Financial Struggles and Promising But Uncertain Horizons

Published Thu, Jan 9 2025 10:05 PM UTC

In an era where the healthcare landscape is constantly evolving, Theratechnologies Inc. finds itself at a critical juncture, grappling with challenges and opportunities that could shape its future. The Montreal-based biopharmaceutical company, known for its innovative therapies, recently announced a significant supply shortage of its product, EGRIFTA SV (tesamorelin for inje...
Clinical Study

Phase 1b Trial of Sudocetaxel Zendusortide Demonstrates Favorable Tolerability and Efficacy in Advanced Ovarian Cance...

Published Tue, Dec 31 2024 1:57 PM UTC

: Theratechnologies has released preliminary tolerability and efficacy data from a Phase 1b, dose-ranging trial of Sudocetaxel Zendusortide, a therapeutic agent designed for patients with advanced ovarian cancer. The trial specifically focused on evaluating the safety profile and potential antitumor activity in heavily pre-treated patient populations. Ovarian cancer remai...
Product Service News

Biopharma Innovations Meet Cyber Fortifications Theratechnologies’ Dual Agenda,

Published Wed, Dec 18 2024 6:31 PM UTC

Biopharmaceutical Innovation and Digital Security: A Dual Frontiers Approach As the biopharmaceutical landscape continues to evolve, companies like Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) are at the forefront of innovation, driving forward their clinical and manufacturing capabilities. Recently, Theratechnologies announced a significant regulatory milestone by submit...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.79
Working Capital Ratio 2.71
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 975,750
Net Income per Employee (TTM) -94,386
Receivable Turnover Ratio (TTM) 22.94
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 1.36

Profitability Ratios Current
Gross Margin (MRQ) 76.19 %
Operating Margin (MRQ) 9.52 %
Net Margin (MRQ) -9.67 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -


  Theratechnologies Inc Outlook

On February 21 2024 the Theratechnologies Inc provided following guidance

Theratechnologies Inc. has announced its financial results for the fourth quarter and full year of fiscal 2023, as well as providing guidance for 2024. The company, which is listed on both the TSX and NASDAQ under the ticker symbols TH and THTX respectively, reported positive business highlights and financial data for the period ending on November 30, 2023.

In their latest report, Theratechnologies estimates show promising outcomes for the future. The company remains focused on the development and commercialization of innovative therapies within the biopharmaceutical sector. The figures provided in the report are in U.S. dollars unless specified otherwise.

Investors and stakeholders can look fo...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.